Literature DB >> 35920131

Artificial intelligence-guided precision treatment of chronic kidney disease-mineral bone disorder.

Adam E Gaweda1, Eleanor D Lederer2,3,4, Michael E Brier1,5.   

Abstract

Chronic kidney disease (CKD)-mineral bone disorder (MBD) is a complex clinical syndrome that begins early during CKD and evolves into one of the deadliest complications of CKD through its effects on the cardiovascular and skeletal systems. Achievement of treatment goals to decrease the risk of accelerated cardiovascular events and fractures has been challenging. We hypothesized that application of quantitative systems pharmacology (QSP) modeling combined with artificial intelligence techniques could improve the management of CKD-MBD with the goal of improving outcomes for patients with CKD. We present the implementation of a reinforcement learning (RL) approach to achieve the prescribed goals for serum calcium, phosphorus, and parathyroid hormone through concurrent dosing of phosphate binders, vitamin D analogs, and calcimimetics by simulation in 80 subjects in Matlab. In silico simulation results demonstrate that the application of a QSP model coupled with RL more effectively and quickly achieves treatment goals even in the setting of inferior simulated subject compliance with medical therapy and identifies key decision variables for therapeutic recommendations.
© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35920131      PMCID: PMC9574726          DOI: 10.1002/psp4.12843

Source DB:  PubMed          Journal:  CPT Pharmacometrics Syst Pharmacol        ISSN: 2163-8306


  18 in total

1.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

2.  Mastering the game of Go without human knowledge.

Authors:  David Silver; Julian Schrittwieser; Karen Simonyan; Ioannis Antonoglou; Aja Huang; Arthur Guez; Thomas Hubert; Lucas Baker; Matthew Lai; Adrian Bolton; Yutian Chen; Timothy Lillicrap; Fan Hui; Laurent Sifre; George van den Driessche; Thore Graepel; Demis Hassabis
Journal:  Nature       Date:  2017-10-18       Impact factor: 49.962

3.  Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder.

Authors:  Adam E Gaweda; Devin E McBride; Eleanor D Lederer; Michael E Brier
Journal:  Am J Physiol Renal Physiol       Date:  2020-12-14

4.  Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.

Authors:  Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew Levey; Paul de Jong; Ron T Gansevoort; Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Ron T Gansevoort; Andrew Levey; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Toshiharu Ninomiya; John Chalmers; Stephen Macmahon; Marcello Tonelli; Brenda Hemmelgarn; Frank Sacks; Gary Curhan; Allan J Collins; Suying Li; Shu-Cheng Chen; K P Hawaii Cohort; Brian J Lee; Areef Ishani; James Neaton; Ken Svendsen; Johannes F E Mann; Salim Yusuf; Koon K Teo; Peggy Gao; Robert G Nelson; William C Knowler; Henk J Bilo; Hanneke Joosten; Nanno Kleefstra; K H Groenier; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley
Journal:  Kidney Int       Date:  2011-02-09       Impact factor: 10.612

5.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

6.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

7.  A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling.

Authors:  Mark C Peterson; Matthew M Riggs
Journal:  Bone       Date:  2009-09-02       Impact factor: 4.398

8.  Inhibition of Osteoclast Differentiation by 1.25-D and the Calcimimetic KP2326 Reveals 1.25-D Resistance in Advanced CKD.

Authors:  Julie Bernardor; Sacha Flammier; Bruno Ranchin; Ségolène Gaillard; Diane Platel; Olivier Peyruchaud; Irma Machuca-Gayet; Justine Bacchetta
Journal:  J Bone Miner Res       Date:  2020-08-06       Impact factor: 6.741

9.  Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification.

Authors:  Aurélien Mary; Thibaut Objois; Michel Brazier; Youssef Bennis; Cédric Boudot; Gaëlle Lenglet; Julien Paccou; Jean-Marc Bugnicourt; Gabriel Choukroun; Tilman B Drueke; Ziad A Massy; Saïd Kamel; Isabelle Six; Romuald Mentaverri
Journal:  Kidney Int       Date:  2021-02-27       Impact factor: 10.612

10.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?

Authors:  M C Peterson; M M Riggs
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-12
View more
  1 in total

1.  Artificial intelligence-guided precision treatment of chronic kidney disease-mineral bone disorder.

Authors:  Adam E Gaweda; Eleanor D Lederer; Michael E Brier
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-08-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.